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Abstract
Introduction: Progestins	are	used	as	conservative	treatment	of	endometrial	hyper‐
plasia	(EH)	and	early	endometrial	cancer	(EEC).	We	aimed	to	assess	whether	immuno‐
histochemical	 expression	 of	 estrogens	 and	 progesterone	 receptors	 (ER	 and	 PR)	
predicts	the	treatment	response.
Material and methods: Electronic	databases	were	searched	for	studies	assessing	ER	
and	PR	expression	in	EH	and	EEC	treated	with	progestins.	Relative	risk	for	poor	re‐
sponse,	sensitivity,	specificity,	diagnostic	odds	ratio	positive	and	negative	likelihood	
ratios	(LR+	and	LR−)	and	area	under	the	curve	(AUC)	on	summary	receiver	operating	
characteristic	curve	were	calculated.	Subgroup	analyses	were	based	on	administra‐
tion	route	 (oral	progestin	or	 levonorgestrel‐intrauterine	device)	and	on	histological	
diagnosis	 (atypical	 EH/EEC	 or	 non‐atypical	 EH).	 Only	 high	 accuracy	 (AUC	>	.9;	
LR+	>10;	LR−	<.1)	was	considered	determining	for	the	clinical	practice.
Results: Thirteen	studies	with	635	patients	were	included	in	the	systematic	review.	
Studies	at	high	risk	of	bias	were	excluded	from	the	meta‐analysis.	Negative	ER	ex‐
pression	did	not	significantly	predict	poor	response	(P	=	.16),	with	low	predictive	ac‐
curacy	 (AUC	=	.637).	 Negative	 PR	 significantly	 predicted	 poor	 response	 (P	=	.01),	
with	moderate	 accuracy	 (AUC	=	.806).	 In	 the	 oral	 progestin	 subgroup,	 neither	 ER	
(P	=	.55)	nor	PR	(P	=	.18)	had	significant	predictive	value.	In	the	levonorgestrel‐intrau‐
terine	device	subgroup,	both	ER	(P	<	.0001)	and	PR	(P	=	.02)	were	significantly	pre‐
dictive	of	good	response,	although	the	accuracy	was	suboptimal	(LR+	6.02	and	2.48,	
respectively;	LR−	.59	and	.55,	respectively).	The	atypical	EH/EEC	subgroup	showed	
non‐significant	results.	Data	about	non‐atypical	EH	were	not	extractable.
Conclusions: ER	and	PR	expressions	are	significantly	predictive	of	response	in	EH	and	
EEC	treated	with	a	 levonorgestrel‐intrauterine	device	but	not	with	oral	progestins.	
However,	their	accuracy	is	insufficient	to	be	determining	in	the	clinical	practice.
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1  | INTRODUC TION
Endometrial	 hyperplasia	 (EH)	 is	 an	 irregular	 proliferation	 of	 endo‐
metrial	 glands	which	 often	 precedes	 endometrial	 cancer	 of	 endo‐
metrioid	type.1‐3	Several	studies	have	shown	that	EH	includes	both	
hyperproliferative	 reactions	 to	 an	 unbalanced	 action	 of	 estrogens	
and	true	precancerous	lesions.1,2,4
The	revised	2014	WHO	classification	of	EH	differentiates	be‐
tween	 these	 two	 conditions	 based	 on	 the	 presence	 of	 cytologi‐
cal	atypia,	identifying	EH	without	atypia	(benign)	and	atypical	EH	
(premalignant).1,2	In	patients	with	EH	without	atypia,	the	20‐year	
risk	of	progression	to	cancer	is	indeed	<5%5;	thus,	these	patients	
may	be	managed	with	observation	alone	and	 follow	up	biopsies,	
while	progestins	are	recommended	in	symptomatic	cases.6
On	the	other	hand,	atypical	EH	requires	a	total	hysterectomy,	al‐
though	progestins	may	be	used	in	women	who	wish	to	preserve	their	
fertility	 or	who	 are	 not	 suitable	 for	 surgery.6	 Such	 a	 conservative	
approach	can	still	be	used	 in	the	well	differentiated,	endometrioid	
type	endometrial	cancer	at	stage	FIGO	Ia	without	tumor	invasion	of	
myometrium	(early	endometrial	cancer,	EEC).7
Although	progestins	are	widely	used	 in	young	women	with	EH	
and	EEC,	they	are	not	always	effective,	and	patients	who	do	not	re‐
spond	are	at	risk	of	progression	to	invasive	disease.8
Thus,	great	efforts	to	find	predictive	markers	of	response	to	pro‐
gestins	have	been	made	in	the	last	years,	including	studies	of	clinical,	
pathological	and	immunohistochemical	features.9‐11
In	particular,	most	studies	focused	on	the	estrogen	receptor	
(ER)	 and	 progesterone	 receptor	 (PR),	 whose	 expression	 is	 eas‐
ily	 assessable	 by	 immunohistochemistry.12‐24	 Estrogens	 are	 in‐
deed	involved	in	the	development	of	EH	and	EC,	and	progestins	
mediate	 their	 action	 through	PR.2,12	 In	 spite	of	 this,	 results	 are	
conflicting	and	 the	possible	predictive	 role	of	ER	and	PR	 is	 still	
undefined.
The	aim	of	this	systematic	review	and	meta‐analysis	was	to	as‐
sess	whether	the	expression	of	ER	and	PR	can	predict	the	response	
to	conservative	treatment	in	EH	and	EEC.
2  | MATERIAL AND METHODS
This	 study	 was	 performed	 following	 the	 SEDATE	 guidelines.25 
The	 study	 protocol	 was	 designed	 a	 priori,	 defining	methods	 for	
collecting,	extracting	and	analyzing	data.	All	 review	stages	were	
conducted	 independently	by	 two	 reviewers	 (A.R.,	A.T.).	The	 two	
authors	 independently	 assessed	 electronic	 search,	 eligibility	 of	
the	studies,	inclusion	criteria,	risk	of	bias,	data	extraction	and	data	
analysis.	Disagreements	were	resolved	by	discussion	with	a	third	
reviewer	(G.S.).
Two	 reviewers	 (A.R.,	 A.T.)	 independently	 conducted	 several	
researches	 using	 MEDLINE,	 Embase,	 Web	 of	 Sciences,	 Scopus,	
ClinicalTrial.gov,	OVID	and	Cochrane	Library	as	electronic	databases.	
A	combination	of	the	following	text	words	from	the	inception	of	each	
database	to	June	2018	was	used:	endometrial	hyperplasia;	endome‐
trial	cancer;	endometrioid	adenocarcinoma;	endometrial	intraepithe‐
lial	neoplasia;	EIN;	therapy;	treatment;	fertility	sparing;	conservative;	
medroxyprogesterone;	 MPA;	 mirena;	 LNG;	 levonorgestrel;	 pro‐
gestogen;	 progestin;	 response;	 resistance;	 persistence;	 outcome;	
progesterone	 receptor;	 PR;	 estrogen	 receptor;	 ER;	 marker;	 immu‐
nohistochemistry;	immunohistochemical.	Review	of	articles	also	in‐
cluded	the	abstracts	of	all	references	retrieved	from	the	search.
This	systematic	review	included	all	studies	meeting	the	following	
inclusion	criteria:
•	 study	 population	 constituted	 of	 women	 diagnosed	 with	 EH	 or	
EEC	and	conservatively	treated	with	progestins;
•	 assessment	of	 the	 expression	of	 the	marker	 (ER	or	PR)	 on	pre‐
treatment	endometrial	specimens	by	immunohistochemistry;
•	 assessment	 of	 the	 association	 between	 the	 expression	 of	 the	
marker	and	the	response	to	therapy.
The	 revised	 tool	 for	 the	quality	assessment	of	 studies	of	di‐
agnostic	accuracy	 included	in	systematic	reviews	(QUADAS‐2)26 
was	used	to	assess	the	risk	of	bias	in	each	study.	Review	authors’	
judgments	were	categorized	as	“low	risk”,	“high	risk”	or	“unclear	
risk	of	bias”	for	each	of	the	four	domains:	(1)	Patient	selection	(low	
risk	if	all	eligible	consecutive	patients	were	included;	unclear	risk	
if	 authors	 did	 not	 specify	 the	 number	 of	 patients	 not	 included;	
high	risk	if	the	study	was	designed	as	case‐control);	(2)	Index	test	
(low	risk	if	authors	clearly	differentiated	between	low	expression	
and	negative	expression	of	hormone	receptors	through	appropri‐
ate	criteria;	unclear	risk	if	criteria	used	were	incomplete;	high	risk	
if	there	was	no	differentiation	between	low	expression	and	nega‐
tive	expression	or	if	individual	patient	data	were	not	reported);	(3)	
K E Y W O R D S
endometrial	cancer,	endometrial	hyperplasia,	endometrial	intraepithelial	neoplasia,	estrogen	
receptor,	hormonal	therapy,	levonorgestrel‐intrauterine	device,	predictive	markers,	
progesterone	receptor,	progestin
Key message
In	endometrial	hyperplasia	and	cancer,	estrogen	or	proges‐
terone	receptor	expression	predicts	the	response	to	a	lev‐
onorgestrel‐intrauterine	device	but	not	to	oral	progestins.	
Their	accuracy	is	insufficient	to	be	routinely	used.
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Reference	test	(low	risk	if	good	response	was	defined	as	absence	
of	any	lesions;	unclear	risk	if	histologic	criteria	defining	good	re‐
sponse	were	 incomplete;	 high	 risk	 if	 authors	 considered	even	 a	
partial	regression	as	good	response);	(4)	Flow	and	timing	(low	risk	
if	 the	follow	up	was	at	 least	3	months;	unclear	risk	 if	 the	follow	
up	was	1‐3	months;	high	risk	if	follow	up	was	<1	months	or	if	hor‐
mone	 receptors	were	assessed	on	biopsies	withdrawn	after	 the	
beginning	of	 the	 treatment).	Domain	2	was	assessed	 separately	
for	ER	and	PR.
Data	were	extracted	from	each	study	without	modification	and	
reported	in	2	×	2	contingency	tables.	For	each	marker,	two	dichot‐
omous	 qualitative	 variables	 were	 assessed:	 immunohistochemical	
expression	on	pretreatment	biopsy	(“positive”	vs	“negative”)	and	re‐
sponse	to	conservative	therapy	(“good”	vs	“poor”).
The	expression	of	 the	marker	was	considered	 “negative”	 if	 the	
percentage	 of	 immunostained	 cells	 was	 <10%;	 otherwise,	 the	 ex‐
pression	was	considered	“positive”.
“Good	response”	indicated	a	complete	regression	of	the	lesion,	
whereas	“poor	response”	indicated	partial	or	no	regression.
If	 discrepancies	 between	 text	 and	 tables	 were	 found,	 values	
from	the	tables	were	used.
Data	were	also	subdivided	into	subgroups	based	on:
•	 administration	route	of	progestins	(oral	or	intrauterine),	due	to	the	
recognized	 superiority	 of	 levonorgestrel‐medicated	 intrauterine	
device	(LNG‐IUD)27‐30;
•	 histological	diagnosis	(atypical	EH/EEC	or	non‐atypical	EH),	since	
the	first	two	are	neoplastic	lesions	and	the	latter	one	is	a	reactive	
condition.31‐34
The	predictive	value	of	ER	and	PR	was	assessed	as	relative	risk	(RR)	
for	failure	of	therapy,	with	95%	confidence	interval	(CI).	RR	was	calcu‐
lated	for	each	study	and	as	pooled	estimate	and	reported	graphically	
on	a	Forest	plot.	P	<	.05	was	considered	significant.
The	statistical	heterogeneity	among	studies	was	assessed	using	
the	inconsistency	index	(I2):	heterogeneity	was	considered	insignifi‐
cant	for	I2 <25%,	low	for	I2 <50%,	moderate	for	I2 <75%	and	high	for	
I2 ≥75%.	If	I2 was	<50%,	a	fixed	effect	model	was	adopted;	otherwise,	
a	random	effects	model	was	preferred.
The	risk	of	bias	across	studies	(publication	bias)	was	assessed	by	
reporting	the	results	on	a	funnel	plot.
We	 calculated	 the	 predictive	 accuracy	 of	 the	 immunohisto‐
chemical	assessment	of	ER	and	PR	to	define	its	clinical	usefulness	in	
predicting	the	response	to	conservative	treatment	of	EH	and	EEC.	
Sensitivity,	 specificity,	 positive	 likelihood	 ratio	 (LR+),	 negative	 like‐
lihood	 ratio	 (LR−)	and	diagnostic	odds	 ratio	 (DOR)	were	calculated	
for	each	study	and	as	pooled	estimate,	and	reported	graphically	on	
Forest	plots,	with	95%	confidence	intervals	(CI).
Area	under	the	curve	(AUC)	was	calculated	on	summary	receiver	
operating	characteristic	(SROC)	curves.	The	predictive	accuracy	was	
considered	low	for	AUC	≤.75,	moderate	for	.75	<	AUC	≤	.9,	high	for	
.9	<	AUC	<	.97,	and	very	high	for	AUC	≥.97.25
The	random	effect	model	of	DerSimonian	and	Laird	was	chosen	
a	priori,	since	an	actual	heterogeneity	is	expected	in	a	meta‐analysis	
of	diagnostic	and	predictive	accuracy.25
We	 defined	 a	 priori	 that	 only	 a	 high	 predictive	 accuracy	
(AUC	>.9)	 would	 have	 indicated	 an	 actual	 clinical	 usefulness,	
since	 conservatively	 treated	 patients	 with	 atypical	 EH	 and	 EEC	
are	 already	 closely	 followed	 with	 endometrial	 biopsies	 every	
3‐6	months	due	 to	 the	 risk	of	progression	 to	 invasive	disease.	 If	
SROC	calculation	was	not	available	due	to	an	insufficient	number	
of	 studies,	we	 adopted	 LR+	 and	 LR−	 as	 surrogates,	which	would	
have	been	>10	and	<.1,	respectively,	to	indicate	an	actual	clinical	
usefulness.25
Data	 analysis	 was	 performed	 using	 REVIEW	 MANAGER	 5.3	
(Copenhagen:	The	Nordic	Cochrane	Centre,	Cochrane	Collaboration,	
2014)	and	META‐DISC	version	1.4	(Clinical	Biostatistics	Unit,	Ramon	
y	Cajal	Hospital,	Madrid,	Spain).
3  | RESULTS
Thirteen	studies	with	a	 total	of	635	patients	were	 included	 in	 the	
systematic	review.12‐24	The	whole	process	of	study	selection	 is	re‐
ported	in	Supporting	Information	Figure	S1.
Four	studies	were	prospective	and	9	were	retrospective.	Sample	
assessed	 included	138	EEC,	162	atypical	EH	and	335	non‐atypical	
EH.	All	EEC	were	G1	endometrioid	adenocarcinoma.	Twelve	of	13	
studies	evaluated	ER,	and	all	13	studies	evaluated	PR.	Patient	age	
ranged	 between	 19	 and	 77	years;	 body	 mass	 index	 (BMI)	 ranged	
between	 17	 and	 70	kg/m2.	 Sampling	methods	 included	 curettage,	
Pipelle	biopsy	and	hysteroscopic	biopsy.	Progestins	administered	in‐
cluded	LNG‐IUD	(n	=	309),	medroxyprogesterone	acetate	(n	=	214),	
megestrol	acetate	(n	=	132),	norethindrone	acetate	(n	=	20)	or	a	mix‐
ture	of	two	or	more	progestins	(n	=	29).
Characteristics	 of	 each	 included	 studies	 are	 reported	 in	 detail	
in	Table	1.
Regarding	risk	of	bias	within	study	assessment,	for	the	“Patient	
selection”	domain,	3	studies	were	considered	to	be	low	risk	of	bias	
and	10	were	considered	unclear	risk	(because	they	did	clearly	not	
state	that	patients	were	consecutive12‐14,16,18,20,22‐24	and/or	that	only	
cancers	with	initial	myometrial	invasion	were	excluded16,19,22,24).
F I G U R E  1  Forest	plots	reporting	relative	risk	for	progestin	therapy	failure	in	estrogen	and	progesterone	receptor	negative	endometrial	
hyperplasia	and	early	endometrial	cancer.	(a)	Overall	analysis	for	estrogen	receptor.	(b)	Subgroup	analysis	for	estrogen	receptor	according	
to	the	administration	route	of	progestins.	(c)	Subgroup	analysis	for	estrogen	receptor	in	patient	with	atypical	hyperplasia	and	cancer.	
(d)	Overall	analysis	for	progesterone	receptor.	(e)	Subgroup	analysis	for	progesterone	receptor	according	to	the	administration	route	of	
progestins.	(f)	Subgroup	analysis	for	progesterone	receptor	in	patient	with	atypical	hyperplasia	and	cancer	[Colour	figure	can	be	viewed	at	
wileyonlinelibrary.com]
     |  5RAFFONE Et Al.
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For	the	“Index	test”	domain,	with	regard	to	ER,	6	studies	were	
considered	 low	 risk,	2	unclear	 risk,	 and	4	high	 risk	 (absence	of	 in‐
dividual	data13,16,18).	With	regard	to	PR,	7	studies	were	considered	
low	risk,	2	unclear	risk	and	4	high	risk	 (3	for	absence	of	 individual	
data13,16,18	and	1	for	not	differentiating	between	low	expression	and	
negative	expression20).
For	the	“Reference	test”	domain,	9	studies	were	considered	low	
risk,	3	studies	unclear	risk	and	1	study	high	risk	(not	differentiating	
between	regression	and	persistence	of	disease24).
For	the	“Flow	and	timing”	domain,	9	studies	were	considered	low	
risk	and	4	unclear	risk.
The	 studies	 at	 high	 risk	 of	 bias	 were	 excluded	 from	 the	
meta‐analysis.
Authors’	 judgments	 about	 risks	 of	 bias	 are	 summarized	 in	
Supporting	Information	Figure	S2.
In	the	main	analysis,	a	negative	expression	of	ER	showed	no	sig‐
nificant	predictive	value,	with	a	RR	of	poor	response	of	2.19	 (95%	
CI	 .74‐6.52;	 P	=	.16),	 with	moderate	 heterogeneity	 among	 studies	
(I2 =	52%)	(Figure	1a).
Sensitivity	 and	 specificity	of	ER	were	 .22	 (95%	CI	 .11‐.37)	 and	
.91	(95%	CI	.88‐.94),	respectively,	with	LR+	and	LR−	of	2.28	(95%	CI	
.81‐6.42)	and	.91	(95%	CI	.72‐1.16),	respectively,	and	a	DOR	of	2.80	
(95%	CI	.70‐11.18).	SROC	analysis	showed	low	predictive	accuracy	
and	no	actual	clinical	usefulness,	with	an	AUC	of	.637.	Heterogeneity	
among	studies	was	low	for	DOR	(I2 =	47.3%),	moderate	for	sensitivity	
(I2 =	70.8%),	LR+	(I2 =	53.6%)	and	LR−	(I2 =	64.2%)	and	high	for	speci‐
ficity	(I2 =	80.6%)	(Figure	2).
A	negative	expression	of	PR	was	significantly	predictive	of	poor	
response,	with	 an	RR	of	2.44	 (95%	CI	1.22‐4.89;	P	=	.01),	without	
heterogeneity	among	studies	(I2 =	0%)	(Figure	1d).
Sensitivity	and	specificity	of	PR	were	 .33	 (95%	CI	 .19‐.50)	and	
.84	(95%	CI	.80‐.88),	respectively,	with	LR+	and	LR−	of	2.37	(95%	CI	
1.47‐3.80)	and	.88	(95%	CI	.65‐1.29),	respectively,	and	a	DOR	of	2.81	
(95%	CI	1.14‐6.93).	SROC	analysis	showed	moderate	predictive	accu‐
racy	and	no	clinical	usefulness,	with	an	AUC	of	.806.	Heterogeneity	
among	studies	was	absent	for	DOR	and	LR+	(I2 =	0%),	low	for	spec‐
ificity	(I2 =	42.3%),	and	moderate	for	sensitivity	(I2 =	73.1%)	and	LR− 
(I2 =	58.1%)	(Figure	3).
In	the	subgroup	of	patients	treated	with	oral	progestins,	ER	was	
not	significantly	predictive	of	response,	with	an	RR	of	 .62	 (95%	CI	
.13‐1.41;	 P	=	.55)	 and	 without	 heterogeneity	 (I2 =	0%)	 (Figure	1b).	
Sensitivity	 and	 specificity	were	 .14	 (95%	CI	 .00‐.58)	 and	 .79	 (95%	
F I G U R E  2  Plots	reporting	prognostic	accuracy	metrics	for	estrogen	receptor	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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CI	 .61‐.91),	 respectively,	with	LR+	 and	LR−	of	 .69	 (95%	CI	 .19‐2.50)	
and	1.28	(95%	CI	.37‐4.45),	respectively,	and	a	DOR	of	.53	(95%	CI	
.05‐5.94).	Heterogeneity	among	studies	was	absent	for	DOR	and	LR+ 
(I2 =	0%),	 low	for	LR−	 (42.0%),	moderate	for	sensitivity	 (66.3%)	and	
high	for	specificity	(95.0%)	(Figure	4a).
In	the	subgroup	of	patients	treated	with	LNG‐IUD,	negative	ex‐
pression	of	ER	was	 significantly	predictive	of	poor	 response,	with	
an	RR	of	7.35	(95%	CI	2.98‐18.16;	P	<	.0001),	without	heterogeneity	
among	studies	(I2 =	0%)	(Figure	1b).	Sensitivity	and	specificity	were	
.50	(95%	CI	.25‐.75)	and	.92	(95%	CI	.87‐.97),	respectively,	with	LR+ 
and	 LR−	 of	 6.02	 (95%	CI	 2.77‐13.10)	 and	 .59	 (95%	CI	 .37‐.94),	 re‐
spectively,	and	a	DOR	of	10.87	(95%	CI	3.35‐35.20).	Heterogeneity	
among	studies	was	absent	for	specificity,	LR+,	LR−	and	DOR	(I2 =	0%),	
and	insignificant	for	sensitivity	(I2 =	7.6%)	(Figure	4b).
In	the	subgroup	of	patients	treated	with	oral	progestins,	PR	was	
not	significantly	predictive	of	response,	with	an	RR	of	2.10	(95%	CI	
.71‐6.24;	 P	=	.18)	 and	 without	 heterogeneity	 (I2 =	0%)	 (Figure	1e).	
Sensitivity	 and	 specificity	were	 .33	 (95%	CI	 .10‐.65)	 and	 .84	 (95%	
CI	.70‐.93),	respectively,	with	LR+	and	LR−	of	2.42	(95%	CI	.93‐6.26)	
and	.80	(95%	CI	.36‐1.78),	respectively,	and	a	DOR	of	3.18	(95%	CI	
.47‐21.51).	Heterogeneity	among	studies	was	absent	for	specificity	
and	LR+	(I2 =	0%),	insignificant	for	DOR	(I2 =	16%),	moderate	for	LR− 
(I2 =	56.6%)	and	high	for	sensitivity	(I2 =	76.6%)	(Figure	5a).
In	the	subgroup	of	patients	treated	with	LNG‐IUD,	negative	ex‐
pression	of	PR	was	significantly	predictive	of	poor	response,	with	an	
RR	of	3.41	 (95%	CI	1.19‐9.77;	P	=	.02),	with	 insignificant	heteroge‐
neity	among	studies	(I2 =	27%)	(Figure	1e).	Sensitivity	and	specificity	
were	.50	(95%	CI	.25‐.75)	and	.81	(95%	CI	.75‐.87),	respectively,	with	
LR+	 and	LR−	of	2.48	 (95%	CI	1.41‐4.38)	and	 .55	 (95%	CI	 .13‐2.32),	
respectively,	and	a	DOR	of	4.04	(95%	CI	.72‐22.57).	Heterogeneity	
among	studies	was	absent	for	LR+	(I2 =	0%),	low	for	DOR	(I2 =	42.6%)	
and	specificity	(I2 =	47.3%),	moderate	for	LR−	(I2 =	63.3%)	and	high	for	
sensitivity	(I2 =	78.1%)	(Figure	5b).
In	the	subgroup	of	patients	with	atypical	EH	and/or	EEC,	ER	was	
not	significantly	predictive	of	response,	with	an	RR	of	.84	(95%	CI	
.29‐2.48;	P	=	.75)	and	without	heterogeneity	 (I2 =	0%)	(Figure	1c).	
Sensitivity	and	specificity	were	.07	(95%	CI	.01‐.23)	and	.90	(95%	
CI	.84‐.95),	respectively,	with	LR+	and	LR−	of	.81	(95%	CI	.29‐2.26)	
and	1.00	 (95%	CI	 .89‐1.12),	 respectively,	and	a	DOR	of	 .83	 (95%	
CI	 .19‐5.89).	 SROC	 analysis	 showed	 no	 predictive	 accuracy	 and	
F I G U R E  3  Plots	reporting	prognostic	accuracy	metrics	for	progesterone	receptor	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
8  |     RAFFONE Et Al.
no	clinical	usefulness,	with	an	AUC	of	.304.	Heterogeneity	among	
studies	 was	 low	 for	 sensitivity	 (I2 =	41%),	 high	 for	 specificity	
(I2 =	88.2%),	and	absent	for	LR+,	LR−	and	DOR	(I2 =	0%)	(Supporting	
Information	Figure	S3).
In	 the	 subgroup	of	 patients	with	 atypical	 EH	and/or	EEC,	PR	
was	 not	 significantly	 predictive	 of	 response,	with	 an	 RR	 of	 1.79	
(95%	 CI	 .70‐4.57;	 P	=	.22)	 and	 without	 heterogeneity	 (I2 =	0%)	
(Figure	1f).	 Sensitivity	 and	 specificity	 were	 .22	 (95%	 CI	 .07‐.44)	
and	 .89	 (95%	 CI	 .82‐.94),	 respectively,	 with	 LR+	 and	 LR−	 of	 2.12	
(95%	 CI	 .90‐5.01)	 and	 .97	 (95%	 CI	 .75‐1.26),	 respectively,	 and	 a	
DOR	 of	 2.18	 (95%	 CI	 .85‐8.61).	 SROC	 analysis	 showed	 moder‐
ate	predictive	accuracy	and	no	actual	clinical	usefulness,	with	an	
AUC	of	.828.	Heterogeneity	among	studies	was	moderate	for	sen‐
sitivity	 (I2 =	71.8%),	 insignificant	 for	 specificity	 (I2 =	.2%),	 low	 for	
LR−	(I2 =	35.5%)	and	absent	for	LR+	and	DOR	(I2 =	0%)	(Supporting	
Information	Figure	S4).
Data	regarding	non‐atypical	EH	were	not	separately	extractable.
In	 the	 assessment	of	 the	 risk	of	bias	 across	 studies	 for	ER,	 al‐
though	the	funnel	plot	showed	an	evident	asymmetry,	 the	studies	
with	 higher	 accuracy	 were	 those	 showing	 the	 higher	 RR	 results	
(Figure	6a).	Thus,	publication	bias	was	absent.
Regarding	PR,	the	funnel	plot	showed	a	clear	symmetry,	thus	ex‐
cluding	the	possibility	of	a	publication	bias	(Figure	6b).
4  | DISCUSSION
Our	 study	 showed	 that	 ER	 and	 PR	 expression	 in	 EH	 and	 EEC	 are	
predictive	of	response	to	LNG‐IUD,	whereas	they	do	not	have	sig‐
nificant	predictive	value	if	oral	progestins	are	administered.
ER	 and	 PR	 are	 nuclear	 receptors	 which	 play	 a	 crucial	 role	 in	
endometrial	 carcinogenesis.	 ER	mediates	 the	 action	 of	 estrogens,	
promoting	 the	 proliferation	 of	 endometrium,	 with	 a	 physiological	
action	in	the	proliferative	phase	of	the	menstrual	cycle.35	When	the	
action	of	estrogens	 is	not	balanced	by	the	action	of	progesterone,	
the	endometrium	goes	through	a	phase	of	disordered	proliferation	
(disordered	 proliferative	 endometrium),	 which	 leads	 to	 EH.36	 The	
increased	 and	 continued	 stimulation	 to	 proliferate	 predisposes	 to	
the	development	of	genetic	mutations	with	the	emergence	of	a	neo‐
plastic	 clone	 (atypical	 EH/endometrioid	 intraepithelial	 neoplasia),	
initiating	 the	 carcinogenesis,4,36	Most	 atypical	 EH	 and	well	 differ‐
entiated	EEC	of	endometrioid	type,	(“type	1	endometrial	cancer”	in	
F I G U R E  4  Forest	plots	reporting	prognostic	accuracy	metrics	for	estrogen	receptor	in	the	subgroup	treated	with	oral	progestins	(a)	and	
LNG‐IUD	(b)	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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the	traditional	classification)	are	still	regulated	by	sexual	hormones,	
with	high	expression	of	ER	and	PR.2,3,22,36	In	the	2013,	the	Cancer	
Genome	Atlas	Network	identified	four	molecular‐based	prognostic	
categories	of	endometrial	cancer	(hypermutated;	ultramutated;	copy	
number	low;	copy	number	high);	of	these,	the	third	one	(classified	as	
microsatellite	stable,	p53	wild	type,	with	low	somatic	copy	number)	
showed	histological	features	superimposable	to	the	“type	1”	endo‐
metrial	cancer,	in	most	cases	showing	high	expression	of	PR.37
Progestins	 have	 been	 widely	 used	 for	 the	 conservative	 treat‐
ment	of	EH	and	EEC,	since	they	antagonize	the	growth‐promoting	
action	of	estrogens,	stimulating	apoptosis	in	endometrial	cells.35,38
Among	 the	 available	 progestin‐based	 treatments,	 LNG‐IUD	
showed	better	efficacy	than	oral	progestin,	as	highlighted	by	several	
meta‐analyses.27‐29	The	 intrauterine	 release	of	 levonorgestrel	pro‐
vides	a	higher	concentration	of	progestin	at	the	level	of	the	uterus,	
leading	to	marked	changes	in	the	endometrium,	similar	to	the	decid‐
ualization	occurring	during	pregnancy.17	On	the	other	hand,	the	local	
action	also	 limits	the	possible	adverse	effects	due	to	the	systemic	
action	of	the	progestin.6
Nonetheless,	there	is	great	uncertainty	in	the	literature	regarding	
the	predictive	value	of	ER	and	PR.	The	2016	ESMO‐ESGO‐ESTRO	
consensus	conference	on	endometrial	cancer	discouraged	the	use	of	
immunohistochemistry	 for	PR	 in	 the	selection	of	patients	 for	con‐
servative	treatment,	stating	that	about	half	of	PR‐null	specimens	still	
respond.7	However,	such	a	statement	is	based	on	only	one	study,15 
and	several	others	showed	different	and	conflicting	 results.	While	
some	studies	advocate	a	high	predictive	utility	of	 these	receptors,	
other	studies	 found	no	associations	between	 their	expression	and	
the	response	to	therapy.	In	our	main	analysis,	we	found	that	ER	was	
not	significantly	predictive	and	had	low	accuracy,	whereas	PR	was	
significantly	 predictive	 of	 response	 (RR),	with	moderate	 accuracy.	
These	 results	might	be	 in	 agreement	with	 the	 scientific	 literature,	
which	has	given	more	importance	to	PR	than	ER.	However,	our	anal‐
yses	highlighted	that	the	results	were	highly	heterogeneous	among	
studies	and	were	strongly	influenced	by	the	administration	route	of	
progestins.
In	the	subgroup	analysis,	we	observed	that	the	predictive	value	
of	ER	and	PR	was	noticeably	higher	if	LNG‐IUD	was	used,	whereas	
F I G U R E  5  Forest	plots	reporting	prognostic	accuracy	metrics	for	progesterone	receptor	in	the	subgroup	treated	with	oral	progestins	(a)	
and	LNG‐IUD	(b)	[Colour	figure	can	be	viewed	at	wileyonlinelibrary.com]
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it	was	not	 significant	 in	 the	case	of	oral	 administration	of	proges‐
tin.	These	results	might	be	explained	by	the	stronger	local	effect	of	
LNG‐IUD:	if	intrauterine	administration	activates	a	higher	percent‐
age	of	PR	 compared	with	 the	oral	 route,	 the	difference	 in	 the	 re‐
sponse	rate	between	PR‐positive	and	PR‐negative	specimens	can	be	
expected	to	become	higher.
In	the	subgroup	of	only	atypical	EH	and	EEC,	the	values	of	RR	
were	not	significant,	with	no	accuracy	for	ER	(AUC	=	.304)	and	mod‐
erate	but	still	insufficient	accuracy	for	PR	(AUC	=	.828).	These	non‐
significant	 results	may	be	explained	by	 the	 fact	 that	no	 studies	 in	
this	 subgroup	exclusively	 considered	LNG‐IUD.	Therefore,	 further	
studies	are	necessary	in	this	regard.
However,	even	in	the	LNG‐IUD	subgroup,	the	predictive	useful‐
ness	appeared	 insufficient,	with	a	 low	sensitivity	 for	both	ER	and	
PR	 (.50).	 This	means	 that	 only	 half	 of	 resistant	 specimens	 have	 a	
loss	of	hormone	receptor	expression.	In	this	regard,	given	the	het‐
erogeneity	of	the	mutational	background	in	endometrial	neoplastic	
specimens,37,39‐41	it	is	possible	that	some	genotypes	are	not	respon‐
sive	 regardless	of	ER	and	PR	expression.	For	example,	 a	 study	by	
Zakhour	et	al42	showed	that	mismatch	repair‐deficient	atypical	EH	
did	not	respond	to	therapy.	Moreover,	other	clinic‐pathological	fac‐
tors	might	affect	the	response	in	the	resistant	cases	when	ER	and	PR	
expression	is	maintained.	On	the	other	hand,	specificity	was	high	for	
both	ER	and	PR,	indicating	that	the	vast	majority	of	responsive	cases	
express	the	hormonal	receptors.	While	being	an	interesting	result,	
in	our	opinion	it	still	is	not	enough	to	be	clinically	useful	in	the	deci‐
sion‐making	between	conservative	treatment	and	hysterectomy,	as	
supported	by	an	AUC	<.9,	an	LR+	<10	and	an	LR−	>.1	for	both	ER	and	
PR.	In	fact,	progestin	therapy	is	not	the	standard	approach,	and	pa‐
tients	with	atypical	EH	and	EEC	who	choose	to	preserve	fertility	are	
closely	 followed	with	endometrial	biopsies	every	3‐6	months,	due	
to	the	risk	of	progression	to	 invasive	disease.	A	predictive	marker	
that	misses	50%	of	non‐responsive	patients	and	addresses	hyster‐
ectomy	 in	 only	 10%‐20%	 of	 patients	who	would	 have	 responded	
definitely,	appears	inadequate,	at	least	as	a	stand‐alone	marker.
In	any	case,	further	studies	might	obtain	better	results	by	assess‐
ing	ER	and	PR	isoforms	(ERα,	ERβ,	PRA,	PRB)	separately	and	on	large	
and	more	homogeneous	samples.
To	the	best	of	our	knowledge,	this	is	the	first	systematic	review	
and	meta‐analysis	assessing	the	predictive	value	or	ER	and	PR	in	the	
conservative	treatment	of	EH	and	EEC,	a	long‐standing	controversial	
issue.
Although	 our	 study	 substantially	 confirms	 the	 guidance	 of	
ESMO‐ESGO‐ESTRO,	 it	may	provide	a	higher	 level	of	evidence	 to	
support	this	position,	which	was	based	on	only	one	small	study.
However,	 there	 are	 some	 limitations	 to	 our	 results.	 The	 small	
number	of	studies	in	the	subgroup	analysis	did	not	allow	us	to	calcu‐
late	AUC	on	SROC	according	to	the	administration	route	of	proges‐
tins,	although	we	could	use	LR+	and	LR−	as	surrogates.
Furthermore,	it	was	impossible	to	extract	data	to	assess	the	pre‐
dictive	value	of	ER	and	PR	separately	for	neoplastic	 lesions	(atypi‐
cal	EH,	EEC)	and	reactive	conditions	(EH	without	atypia)	in	patients	
treated	with	LNG‐IUD,	which	was	 the	subgroup	showing	 the	best	
results.
5  | CONCLUSION
ER	and	PR	expression	 in	EH	and	EEC	are	predictive	of	response	to	
LNG‐IUD,	but	not	to	oral	progestins.	However,	given	the	low	sensi‐
tivity	and	the	suboptimal	specificity,	they	do	not	appear	adequate	as	
predictive	markers	if	assessed	alone.	Further	studies	in	this	field	may	
better	assess	 separately	 the	predictive	value	of	ER	and	PR	 in	each	
specific	histological	category	(EH	with	and	without	atypia	and	EEC)	
and	with	regard	to	their	receptor	isoforms,	and	how	it	can	be	affected	
by	the	mutational	background	and	the	clinicopathological	factors.
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